This is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. The study is designed to describe the relationship between multiple doses and pharmacokinetic/pharmacodynamic parameters of DA-1229 as well as safety profile.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
110
Clinical Trials Center, Seoul National University Hospital
Seoul, Chongo-Gu, Yon-Gon Dong, South Korea
RECRUITINGTo characterize the pharmacokinetic/pharmacodynamic of DA-1229 in healthy male subjects
Time frame: Multiple blood and urine samples will be collected for 120 hours after dosing of DA-1229
To evaluate the safety and tolerance of DA-1229
Time frame: up to 10 days (single dose study), 17 days (single dose study for food effect), 20 days (multiple dose study)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.